July 17, 2023

  Research findings says people who took Paxlovid are less likely to have long COVID symptoms. The article was published in March 2023 in JAMA Internal Medicine. It revealed that high-risk patients who took Paxlovid within five days of confirming infection for COVID-19 were 26% less likely to have Long COVID symptoms after 90 days, compared […]

0
By Dr. Emmanuel Egbroko
July 17, 2023

   Jennifer Lorenzini/Reuters   The U.S Food and Drug Administration (FDA) approves Paxlovid for the treatment of mild-to-moderate COVID-19. In a press release On May 25, 2023, the FDA granted Pfizer approval for its antiviral medication for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including […]

0
By Dr. Emmanuel Egbroko
July 15, 2023

  Paxlovid reduces risk of severe COVID-19 in patients with chronic health condition a new study finds. The study which was conducted by researchers at Harvard University was published in June 2023 in the Clinical Infectious Diseases Journal. This investigation will contribute to proper use of the antiviral medication in the treatment of patients in […]

0
By Dr. Emmanuel Egbroko
July 15, 2023

  Paxlovid is an oral antiviral medication for the treatment of COVID-19. It was developed by Pfizer for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease, including hospitalization and death. The Food and Drug Administration (FDA) first made Paxlovid available in December 2021 under emergency use authorization for high-risk individuals […]

0
By Dr. Emmanuel Egbroko